personalized cancer vaccine + pembrolizumab

The combination of a personalized cancer vaccine and pembrolizumab (Keytruda) represents a cutting-edge approach in cancer immunotherapy, particularly in the adjuvant setting. Personalized cancer vaccines, such as the mRNA-based individualized neoantigen therapy intismeran autogene (V940/mRNA-4157) developed by Moderna and Merck, are custom-manufactured for each patient. By sequencing the patient's tumor and healthy DNA, researchers identify unique tumor-specific mutations (neoantigens) and design a vaccine (often encoding up to 34 neoantigens) to train the patient's immune system to recognize and destroy residual cancer cells. Pembrolizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, acts as an immune checkpoint inhibitor that prevents PD-1 from binding to its ligands (PD-L1 and PD-L2), thereby releasing the brakes on T-cell activation. When administered together, the personalized vaccine primes and expands neoantigen-specific T-cells, while pembrolizumab amplifies and sustains this anti-tumor immune response by preventing T-cell exhaustion. This combination has demonstrated landmark efficacy in clinical trials, notably reducing the risk of recurrence or death by 42% compared to pembrolizumab alone in patients with completely resected high-risk melanoma (Phase 3 INTerpath-001 trial), and is being actively investigated across other solid tumors including non-small cell lung cancer, bladder cancer, and renal cell carcinoma.